Trending Topic

Thyroid gland inside human body. 3D illustration
5 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Thyroid eye disease (TED), also known as Graves’ orbitopathy, is a complex autoimmune disorder driven by an interplay of immune cells, orbital fibroblasts and tissue remodelling factors that lead to inflammation, oedema and, ultimately, potential vision loss.1 While the disease has historically been challenging to manage, recent therapeutic innovations are reshaping treatment paradigms and offering new […]

Chronic Kidney Disease

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.

34 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT OPINIONS
Prof. Aleš Linhart, Dr Eric Wallace, Prof. William Wilcox

Fabry disease experts discuss early diagnosis, organ monitoring, long-term individualized care and future directions.

34 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION
Prof. Bradley Erickson, Prof. Neera Dahl, Prof. Charles Vega

Watch three experts discuss the clinical management of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).

Developed by Touch
Coverage from: EASD Highlights

Finerenone (a selective nonsteroidal mineralocorticoid receptor antagonist) and the SGLT2 inhibitor empagliflozin may reduce both kidney and cardiovascular risks in people with chronic kidney disease and type 2 diabetes. It is unknown whether dual therapy with finerenone and empagliflozin is superior ...

Developed by Touch
Coverage from: EASD Highlights

There is a high unmet need for new treatments to preserve kidney function and delay kidney disease progression in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). In this touchENDOCRINOLOGY interview, Prof. Jennifer Green (Duke University School ...

38 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

Watch experts in endocrinology and in primary care discuss key considerations for addressing cardiorenal outcomes in patients with CKD/T2D

Developed by Touch
Coverage from: EASD Highlights

SUSTAIN 6 and PIONEER 6 investigated the effects of semaglutide versus placebo on major adverse cardiovascular events (MACE). The current post hoc analysis investigated the association between baseline kidney function and risk of MACE, and the effect of semaglutide on risk of ...

Developed by Touch
Coverage from: ADCES Highlights

Chronic kidney disease (CKD) is a common diabetes-related complication among type 2 diabetes (T2DM) patients, with a high prevelance within primary care settings. In this touchENDOCRINOLOGY interview, we speak with Dr Sara (Mandy) Reece (Philadelphia College of Osteopathic Medicine (PCOM), ...

Developed by Touch
Coverage from: ADA Highlights

The current treatment options for chronic kidney disease in patients with type 2 diabetes is discussed by Professor Hiddo Heerspink (University Medical Center Groningen, Groningen, Netherlands). Also discussed is the mechanism of tirzepatide, a novel once-weekly medication, which has shown to ...

Developed by Touch
Coverage from: ADA Highlights

A pre-specific exploratory analysis of SURPASS-4 evaluated the progression to pre-specified kidney endpoints between tirzepatide and titrated daily insulin glargine in chronic kidney disease. Professor Hiddo Heerspink (University Medical Center Groningen, Groningen, Netherlands) discusses the outcome of the analysis and ...

Developed by Touch
Coverage from: ADA Highlights

The combined use of finerenone and glucagon-like peptide-1 receptor agonist (GLP-1RA) for chronic kidney disease (CKD) and type 2 diabetes (T2D) was studied in the FIDELITY analysis, and is discussed by Professor Peter Rossing (Steno Diabetes Center, Copenhagen, Denmark). ...

Kidney Research UK in collaboration with Dr James Burton highlight the unmet needs in research, the urgency and importance of transforming treatments for people living with kidney disease. Find out more at: https://www.kidneyresearchuk.org/ Support: Published in collaboration ...

Kidney Research UK in collaboration with Dr James Burton highlight the unmet needs in research, the urgency and importance of transforming treatments for people living with kidney disease. Find out more at: https://www.kidneyresearchuk.org/ Support: Published in collaboration ...

Mark CompleteCompleted
BookmarkBookmarked
Luis D’Marco, María Jesús Puchades, Lorena Gandía

Chronic kidney disease (CKD) represents one of the greatest future public health challenges due, among other consequences, to its elevated burden on economic and human resources within healthcare systems.1 Moreover, the rapid growth of type 2 diabetes mellitus (T2DM) results ...

Mark CompleteCompleted
BookmarkBookmarked

Hyperinsulinaemic Hypoglycaemia (HH) is a very rare disease with an estimated incidence of 1/50,000,1 and includes a clinical, histological and genetic heterogeneous group of disorders characterised by hypoglycaemia, hyperinsulinism or, more specifically, increased C-peptide level and inappropriate low blood levels of ...

Load More...
Close Popup